Actively Recruiting

Phase 3
Age: 18Years +
All Genders
NCT07059377

Semaglutide for Smoking Cessation in Patients With Diabetes

Led by Ottawa Heart Institute Research Corporation · Updated on 2026-05-11

100

Participants Needed

1

Research Sites

71 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

To assess the feasibility of conducting a randomized controlled trial (RCT) to determine the effectiveness of semaglutide as an adjunct to combination NRT in supporting smoking cessation for patients with diabetes.

CONDITIONS

Official Title

Semaglutide for Smoking Cessation in Patients With Diabetes

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults (18 years or older) with type 2 diabetes
  • Currently residing in Ontario
  • Smoke at least five cigarettes per day and willing to reduce or quit smoking within the next 6 months
  • Stable HbA1c 7.0% - 10% with no more than a 1% change over the last 3 to 6 months
  • Have not used GLP-1 receptor agonists in the past six months
  • Able to provide informed consent
Not Eligible

You will not qualify if you...

  • Pregnant or breastfeeding individuals
  • Contraindication to nicotine replacement therapy or GLP-1 receptor agonists
  • Current daily use of nicotine replacement therapy or GLP-1 receptor agonists
  • Use of bupropion, cytisine, or varenicline within the last 7 days
  • Use of DPP-IV inhibitor within the last 7 days
  • Initiation of a new diabetes medication within the last 3 months
  • Personal or family history of medullary thyroid cancer
  • Personal or family history of Multiple Endocrine Neoplasia syndrome type 2
  • Diabetic ketoacidosis
  • Type I diabetes
  • Acute pancreatitis or pancreatic cancer
  • Acute, chronic, or end-stage renal failure
  • Tachyarrhythmias
  • Unable to engage in follow-up for any reason, for example acute mental illness, cognitive impairment, or unable to speak English or French
  • Other conditions deemed by the study team to interfere with participation or outcomes, such as being acutely unwell or having a life expectancy less than 1 year

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

University of Ottawa Heart Institute

Ottawa, Ontario, Canada, K1Y 4W7

Actively Recruiting

Loading map...

Research Team

E

Evyanne Quirouette

CONTACT

N

Nidhi Agrawal

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here